Breaking News

AMAG Pharma Appoints Pharmacovigilance VP

September 16, 2014

Johnson to oversee product safety and compliance

Judith Johnson, M.D., has rejoined AMAG Pharmaceuticals as vice president of pharmacovigilance and pharmacoepidemiology, responsible for all pharmacovigilance functions, including product safety surveillance, aggregate safety reporting, pharmacoepidemiology and risk management. She will also oversee the company's compliance with FDA and regulatory requirements for Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse.
 
For the past ten years, Dr. Johnson has held leadership roles in pharmacovigilance and drug safety at companies including EMD Serono, Inc., AMAG, Genzyme and Parexel.  
 
"Judy brings with her a wealth of experience and ability in the areas of drug safety and risk management, which will be critical for the future success of AMAG as we work to build a diversified, multi-product pharmaceutical company," said Steven Caffe, M.D., senior vice president, chief development and regulatory officer at AMAG

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks